

(aa) sequence of any one of the strands in the front beta -sheet (fbS), any of the connecting loops and/or any of the B', I or D strands in the back beta -sheet (bbS). Also new are: (1) dimers, oligomers and multimers of (I); (2) isolated DNA (II) that encodes (I); (3) (expression) vectors containing (II); (4) hosts transformed with the expression vector, and (5) fusion proteins (FP) of (I) with an immunological adjuvant.

USE - Cells of (4) are used to produce recombinant (I) which are used as vaccines for treatment or prevention of diseases associated with excessive release or activity of (Ia), e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, cancer of any sort, disseminated sclerosis, diabetes, psoriasis, osteoporosis and asthma. Ab are also useful as diagnostic immunoassay reagents, while (II) is a source of primers and probes, and used for expressing (I) in vivo (DNA vaccines).

ADVANTAGE - (I) have no residual TNF activity, are immunogenic in a large proportion of the human population (by using promiscuous epitopes) and are optimised for production of neutralising Ab.

Dwg.5a4/16

FS CPI

FA AB; GI

MC CPI: B04-E02B; B04-E08; B04-F0100E; B04-G02; B04-G21; B04-H08; B04-H0800E; B11-C07A; B12-K04A; B14-C09B; B14-E10C; B14-H01; B14-K01A; B14-N01; B14-N17; B14-S04; B14-S11; D05-H07; D05-H09; D05-H12B; D05-H12C; D05-H12D1; D05-H12E; D05-H14; D05-H17A5; D05-H17B2; D05-H17C

=> d his

(FILE 'HOME' ENTERED AT 14:08:18 ON 05 JUL 2006)

FILE 'HCAPLUS' ENTERED AT 14:08:26 ON 05 JUL 2006

```

      E T CELLS/CT
      E E3+ALL
      E E2
L1      64804 E3-26
      E E3+ALL
L2      115894 E25+OLD,NT
      E TUMOR ANTIGEN/CT
L3      4738 E6-14
      E E6+ALL
L4      36596 E5+OLD,NT
      E CYTOMEGALOVIRUS/CT
      E E3+ALL
L5      9574 E7+OLD,NT
      E ADENOVIRUS/CT
      E E3+ALL
      E E2
      E E3+ALL
L6      12821 E5+OLD,NT
      E HUMAN ADENOVIRUS/CT
      E E3+ALL
L7      5343 E7+NT
L8      201 L1-2 AND L3-4 AND L5-7
L9      6 L8 AND (BISPECIF? OR BI SPECIF?)
      E ANTIGENS/CT
      E E3+ALL
L10     23628 E2+NT (L) VIR?
L11     376 L1-2 AND L3-4 AND L10
L12     8 L11 AND (BISPECIF? OR BI SPECIF?)
L13     7 L12 NOT L9
      SEL AN 1-2
L14     2 E1-4 AND L13
```

FILE 'WPIX' ENTERED AT 14:42:09 ON 05 JUL 2006

E COOPER L/AU

L15 123 E3-22
E JENSEN M/AU
L16 314 E3-29
L17 265 (CITY (1N)HOPE)/PA,CS
E CITY/PACO
E E3+ALL
L18 264 CITY/PACO
L19 8053 (B04-B04D1 OR C04-B04D1 OR B04-F04 OR C04-F04)/MC
L20 19132 S T CELL# OR LYMPHOCYT?
L21 97277 (B14-H? OR C14-H? OR B12-G05 OR C12-G05 OR B12-G07 OR C12-G07)/
L22 25313 A61P035/IPC, IC, ICM, ICS, ICA, ICI
L23 317 (B04-B04C8 OR C04-B04C8)/MC
L24 62302 (B14-A02? OR C14-A02? OR B14-A06 OR C14-A06)/MC OR (V560 OR P21
L25 10912 (A61P031-12 OR A61P031-14 OR A61P031-16 OR A61P031-18 OR A61P03
L26 42 (A61P031:12 OR A61P031:14 OR A61P031:16 OR A61P031:18 OR A61P03
L27 1626 L19 AND L21-22
L28 30 L19 AND L23
L29 0 L27-28 AND L15-18
L30 41 L15-18 AND L19-20
L31 12 L30 AND L21-23
L32 0 L31 AND L24-26
L33 445 L27 AND L24-26
L34 4 L28 AND L24-26
L35 183 L33 NOT (PY>2003 OR AY>2003 OR PRY>2003)
L36 2 L35 AND (BISPECIF? OR BI SPECIF?)

=>

*T-Lymphocytes, Cytotoxic: IM, immunology

T-Lymphocytes, Cytotoxic: ME, metabolism

CN 0 (Antigens, Differentiation, T-Lymphocyte); 0 (Antigens, Ly); 0
(Antigens, Neoplasm); 0 (Antigens, Surface); 0 (Epitopes); 0 (H-2
Antigens); 0 (Histocompatibility Antigens Class II); 0 (Monokines); 0
(Proteins)

=> d his

(FILE 'HOME' ENTERED AT 12:36:49 ON 05 JUL 2006)

FILE 'MEDLINE' ENTERED AT 12:39:30 ON 05 JUL 2006

```

L1      487 E3-27,E36
          E JENSEN M/AU
          E JENSEN M/AU
L2      988 E3-27
          E JENSEN MI/AU
L3      79 E4-14
L4      2556 (CITY(1N)HOPE)/CS
          E T-CELL/CT
          E E3+ALL
          E E2
          E E3+ALL
L5      184732 E16+NT
          E T-CELL/CT
          E E7+ALL
          E E2
          E E3+ALL
L6      26481 E8+NT
          E E31
L7      191321 L5-6
L8      150 L1-4 AND L7
          E TUMOR ANTIGEN/CT
          E E4+ALL
          E E2
          E E3+ALL
L9      63574 E4+NT
L10     8 L8 AND L9
L11     5573 L7 AND L9
          E VIRAL ANTIGENS/CT
          E E3+ALL
          E E2+ALL
L12     75227 E4+NT
          E INFLUENZA/CT
          E INFLUENZA VIRUS/CT
          E E3+ALL
          E E2
          E E3+ALL
L13     21153 E7+NT
          E CMV/CT
          E CYTOMEGALOVIRUS/CT
          E CYTOMEGALOVIRUS/CT
          E E3+ALL
L14     12567 E9
L15     478 L11 AND L12-14
L16     3 L15 AND (BISPECIF? OR BI SPECIF?)
L17     427 L15 AND PY<=2003
L18     472 L5 AND L9 AND L12-14
L19     43 L18 AND L6
L20     0 L19 AND L1-4
L21     37 L19 AND PY<=2003
          SEL AN 4 L21
L22     1 E1 AND L21
L23     0 L10 AND L12-14

```

L24 9 L10,L22

FILE 'EMBASE' ENTERED AT 13:04:59 ON 05 JUL 2006

```

      E T-CELL/CT
      E T CELL/CT
      E E3+ALL
      E E2
      E E3+ALL
L25 170439 E22+NT
      E T CELL/CT
      E E42+ALL
      E E2
      E E3+ALL
L26 20167 E1
      E TUMOR ANTIGEN/CT
      E E3+ALL
L27 62056 E13+NT
      E VIRAL ANTIGEN/CT
      E E3+ALL
      E E2+ALL
L28 36303 E18+NT
      E INFLUENZA/CT
      E E3+ALL
L29 11331 E2
      E INFLUENZA VIRUS/CT
      E E3+ALL
L30 15248 E5+NT
L31 181 L25 AND L27 AND L28-30
L32 13 L31 AND L26
L33 1 L31 AND (BISPECIF? OR BI SPECIF?)
L34 167 L31 NOT L32-33
L35 132 L34 AND PY<=2003

```

=> b hcap

FILE 'HCAPLUS' ENTERED AT 14:21:49 ON 05 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Jul 2006 VOL 145 ISS 2

FILE LAST UPDATED: 4 Jul 2006 (20060704/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all l14 tot

```

L14 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:610065 HCAPLUS
DN 139:148464
ED Entered STN: 08 Aug 2003
TI Bi-specific chimeric T cells for adoptive
immunotherapy

```

FBL-immune spleen cells with α L3T4 plus complement before culture, as well as the direct addition of α L3T4 to cultures, diminished the generation of FBL-specific CTL. The contribution of L3T4+ cells could be completely replaced by the addition of exogenous cytokines. The data demonstrate that the optimal generation of FBL-specific Lyt-2+ CTL requires the presence of L3T4+ cells, presumably to provide necessary lymphokines. FBL-specific CTL could not be generated from purified FBL-immune T cells in the absence of AC. Syngeneic Ia+ macrophages (M.vphi.), added at the initiation of culture, restored the response of purified T cells. Pretreatment of M.vphi. with ammonium chloride or chloroquine, or the addition of monoclonal α I-Ab antibody at the initiation of culture, inhibited the ability of M.vphi. to reconstitute the CTL response. Finally, the addition of exogenous helper factors could replace M.vphi. and reconstitute the FBL-specific response of AC-depleted immune T cells. These results suggest that during the generation of Lyt-2+ CTL to a syngeneic tumor expressing only class I major histocompatibility complex antigens, Ia+ AC are required to biochem. process antigen released from the tumor cells and present this modified antigen to class II-restricted T helper cells.

ST cytotoxic T lymphocyte class II antigen; tumor antigen cytotoxic T lymphocyte
 IT Neoplasm
 (cytotoxic T-lymphocytes specific for, generation of, accessory and helper cells and factors in)
 IT Macrophage
 (in cytotoxic T-lymphocyte generation)
 IT Lymphocyte
 (T-, cytotoxic, formation of, accessory and helper cells and factors in, in immune response to tumor)
 IT Lymphocyte
 (T-, helper, helper lymphokine of, in cytotoxic T-lymphocyte generation)
 IT Lymphokines and Cytokines
 RL: BIOL (Biological study)
 (helper factor, in cytotoxic T-lymphocyte generation, in immune response to tumor)
 IT Antigens
 RL: BIOL (Biological study)
 (histocompatibility, class II, in cytotoxic T-lymphocyte generation, in immune response to tumor)

=> d his

(FILE 'HOME' ENTERED AT 10:39:01 ON 05 JUL 2006)

FILE 'HCAPLUS' ENTERED AT 10:39:08 ON 05 JUL 2006

L1 2 US2005129671/PN OR (US2004-797609 OR US2003-453197#)/AP,PRN
 E COOPER L/AU
 L2 174 E3-24
 E COOPER LAURENCE/AU
 L3 27 E3-6
 E COOPER LAWRENCE/AU
 L4 6 E4-9
 E JENSEN M/AU
 L5 395 E3-36
 E JENSEN MIKE/AU
 L6 2 E3
 E JENSEN MICHAEL/AU
 L7 397 E3-31
 L8 3491 (CITY (1N)HOPE)/CS,PA
 E T CELL/CT
 L9 64804 E8-31
 E E8+ALL
 L10 115894 E25+OLD,NT
 L11 115894 L9-10

```

      E ANTIGEN/CT
      E ANTIGENS/CT
      E E3+ALL
L12    286310 E2+NT
      E E81+ALL
L13    23367 E11+OLD,NT
      E ANTIGEN-PRESENTING CELL/CT
      E E3+ALL
L14    15438 E6+NT
      E TUMOR ANTIGENS/CT
L15    4738 E3-11
      E E3+ALL
L16    36596 E5+OLD,NT
L17    4461 L11 AND L15-16
      E VIRAL ANTIGENS/CT
L18    4461 L17 AND L12-14
      E INFLUENZA/CT
      E E3+ALL
L19    2350 E3
      E INFLUENZA/CT
      E E6+ALL
L20    5083 E8+OLD
      E INFLUENZA B VIRUS/CT
      E E9+ALL
L21    12161 E7+OLD,NT
      E EBV/CT
      E E3+ALL
      E E2
L22    9203 E3-9
      E E3+ALL
L23    8256 E8+OLD
      E LYMPHOCRYPTOVIRUS/CT
      E E3+ALL
      E HUMAN HERPESVIRUS 5/CT
      E E3+ALL
L24    4280 E8+OLD
      E HUMAN HERPESVIRUS 6+ALL/CT
L25    866 E8+OLD,NT
      E HUMAN HERPESVIRUS 7/CT
      E E3+ALL
L26    340 E7+OLD
      E HUMAN HERPESVIRUS 8/CT
      E E3+ALL
L27    1421 E8
L28    12 L18 AND L1-8
L29    268 L18 AND L19-27
L30    235 L29 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
L31    7 L30 AND (BISPECIF? OR BI SPECIF?)
L32    1 L31 AND L1-8
L33    6 L31 NOT L32
      SEL AN 3
L34    1 E1-2 AND L33
L35    13 L28,L34

```

FILE 'HCAPLUS' ENTERED AT 11:03:45 ON 05 JUL 2006

=> b medl

FILE 'MEDLINE' ENTERED AT 13:04:42 ON 05 JUL 2006

FILE LAST UPDATED: 4 JUL 2006 (20060704/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).

See also: